A Randomised Controlled Trial of the Efficacy and Safety of Alemtuzumab (MABCAMPATH) for Prevention of Graft Rejection and Preservation of Renal Function in Patients Receiving Kidney Transplants

Trial Profile

A Randomised Controlled Trial of the Efficacy and Safety of Alemtuzumab (MABCAMPATH) for Prevention of Graft Rejection and Preservation of Renal Function in Patients Receiving Kidney Transplants

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Azathioprine; Corticosteroids; Methylprednisolone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms CAMP-ASIA2
  • Most Recent Events

    • 16 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top